At a glance
- Originator Taisho Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Calpain inhibitors; Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Cataracts
Most Recent Events
- 10 Nov 2006 Discontinued - Preclinical for Cancer in Japan (unspecified route)
- 10 Nov 2006 Discontinued - Preclinical for Cataracts in Germany (unspecified route)
- 10 May 2000 Preclinical development for Cataracts in Germany (Unknown route)